207 related articles for article (PubMed ID: 32908002)
1. Enhancing KDM5A and TLR activity improves the response to immune checkpoint blockade.
Wang L; Gao Y; Zhang G; Li D; Wang Z; Zhang J; Hermida LC; He L; Wang Z; Si J; Geng S; Ai R; Ning F; Cheng C; Deng H; Dimitrov DS; Sun Y; Huang Y; Wang D; Hu X; Wei Z; Wang W; Liao X
Sci Transl Med; 2020 Sep; 12(560):. PubMed ID: 32908002
[TBL] [Abstract][Full Text] [Related]
2. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
5. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.
Malo ME; Allen KJH; Jiao R; Frank C; Rickles D; Dadachova E
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218169
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
9. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade.
Chen IX; Newcomer K; Pauken KE; Juneja VR; Naxerova K; Wu MW; Pinter M; Sen DR; Singer M; Sharpe AH; Jain RK
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23684-23694. PubMed ID: 32907939
[TBL] [Abstract][Full Text] [Related]
10. PAK4 inhibition improves PD-1 blockade immunotherapy.
Abril-Rodriguez G; Torrejon DY; Liu W; Zaretsky JM; Nowicki TS; Tsoi J; Puig-Saus C; Baselga-Carretero I; Medina E; Quist MJ; Garcia AJ; Senapedis W; Baloglu E; Kalbasi A; Cheung-Lau G; Berent-Maoz B; Comin-Anduix B; Hu-Lieskovan S; Wang CY; Grasso CS; Ribas A
Nat Cancer; 2020; 1(1):46-58. PubMed ID: 34368780
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance.
Zhou X; Ni Y; Liang X; Lin Y; An B; He X; Zhao X
Front Immunol; 2022; 13():915094. PubMed ID: 36189283
[TBL] [Abstract][Full Text] [Related]
12. Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment.
Zemek RM; De Jong E; Chin WL; Schuster IS; Fear VS; Casey TH; Forbes C; Dart SJ; Leslie C; Zaitouny A; Small M; Boon L; Forrest ARR; Muiri DO; Degli-Esposti MA; Millward MJ; Nowak AK; Lassmann T; Bosco A; Lake RA; Lesterhuis WJ
Sci Transl Med; 2019 Jul; 11(501):. PubMed ID: 31316010
[TBL] [Abstract][Full Text] [Related]
13. An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Kumagai S; Togashi Y; Sakai C; Kawazoe A; Kawazu M; Ueno T; Sato E; Kuwata T; Kinoshita T; Yamamoto M; Nomura S; Tsukamoto T; Mano H; Shitara K; Nishikawa H
Immunity; 2020 Jul; 53(1):187-203.e8. PubMed ID: 32640259
[TBL] [Abstract][Full Text] [Related]
14. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
16. Combination of Photodynamic Therapy and a Flagellin-Adjuvanted Cancer Vaccine Potentiated the Anti-PD-1-Mediated Melanoma Suppression.
Hwang HS; Cherukula K; Bang YJ; Vijayan V; Moon MJ; Thiruppathi J; Puth S; Jeong YY; Park IK; Lee SE; Rhee JH
Cells; 2020 Nov; 9(11):. PubMed ID: 33171765
[TBL] [Abstract][Full Text] [Related]
17. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
18. Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
Tachinami H; Nishii N; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Tomihara K; Noguchi M; Azuma M
Oral Oncol; 2019 Apr; 91():21-28. PubMed ID: 30926058
[TBL] [Abstract][Full Text] [Related]
19. Histone demethylase KDM5A is transactivated by the transcription factor C/EBPβ and promotes preadipocyte differentiation by inhibiting Wnt/β-catenin signaling.
Guo L; Guo YY; Li BY; Peng WQ; Tang QQ
J Biol Chem; 2019 Jun; 294(24):9642-9654. PubMed ID: 31061100
[TBL] [Abstract][Full Text] [Related]
20. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.
Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
